联邦法官阻止药店生产更廉价的减重药品复制品Ozempic和Wegovy。 Federal judge blocks compounding pharmacies from producing cheaper replicas of weight loss drugs Ozempic and Wegovy.

德克萨斯州的一名联邦法官拒绝了复方药房的初步禁令请求，这些药房寻求继续生产诺和诺德的减肥药 Ozempic 和 Wegovy 的廉价版本。 A federal judge in Texas has denied a preliminary injunction request from compounding pharmacies seeking to continue producing cheaper versions of Novo Nordisk's weight loss drugs, Ozempic and Wegovy. 决定意味着小型化合物必须立即停止生产,而规模更大的、获得联邦许可的化合物在5月22日之前必须停止生产。 The decision means small-scale compounders must stop production immediately, while larger, federally licensed compounders have until May 22. 美国食品和药物管理局宣布结束这些药物的活性成分西马格卢提德的短缺, This follows the FDA declaring an end to the shortage of semaglutide, the active ingredient in these drugs, and comes amid concerns over the safety and efficacy of compounded versions.